Dr. Abhishek Tripathi, MD
Claim this profileUniversity of Oklahoma Health Sciences Center
Expert in Cancer
Expert in Bladder Cancer
21 reported clinical trials
44 drugs studied
About Abhishek Tripathi, MD
Education:
- Earned an MD from Maulana Azad Medical College.
- Completed a Residency in Internal Medicine at UMass Chan Medical School.
- Undertook a Fellowship in Oncology/Hematology.
Experience:
- Former faculty member at the University of Oklahoma Stephenson Cancer Center.
- Currently specializes in genitourinary malignancies at the City of Hope Comprehensive Cancer Center.
- Recognized with the Conquer Cancer Foundation of ASCO Merit Award in 2017.
Area of expertise
1Cancer
Global LeaderStage IV
Stage III
HER2 positive
2Bladder Cancer
Global LeaderStage IV
Stage III
HER2 positive
Affiliated Hospitals
Clinical Trials Abhishek Tripathi, MD is currently running
Eribulin + Chemotherapy
for Bladder Cancer
This phase III trial compares the usual chemotherapy treatment to eribulin plus gemcitabine in treating patients with urothelial cancer that has spread to other places in the body (metastatic). Chemotherapy drugs, such as eribulin, gemcitabine, docetaxel, paclitaxel, and sacituzumab govitecan work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. This trial aims to see whether adding eribulin to standard of care chemotherapy may work better in treating patients with metastatic urothelial cancer.
Recruiting2 awards Phase 3
Radioactive Drug Therapy
for Prostate Cancer
This trial studies how well lutetium Lu 177 dotatate works in treating patients with a specific type of prostate cancer that has spread. The drug targets cancer cells and releases radiation to kill them. Lutetium-177 (Lu-177) PSMA therapy is a targeted treatment for advanced prostate cancer that has shown promising results.
Recruiting1 award Phase 216 criteria
More about Abhishek Tripathi, MD
Clinical Trial Related3 years of experience running clinical trials · Led 21 trials as a Principal Investigator · 11 Active Clinical TrialsTreatments Abhishek Tripathi, MD has experience with
- Pembrolizumab
- Gemcitabine Hydrochloride
- Nivolumab
- Avelumab
- Cisplatin
- Durvalumab
Breakdown of trials Abhishek Tripathi, MD has run
Cancer
Bladder Cancer
Transitional Cell Carcinoma
Prostate Cancer
Other Doctors you might be interested in
Frequently asked questions
Do I need insurance to participate in a trial?
Almost all clinical trials will cover the cost of the ‘trial drug’ — so no insurance is required for this. For trials where this trial drug is given alongside an already-approved medication, there may be a cost (which your insurance would normally cover).
What does Abhishek Tripathi, MD specialize in?
Abhishek Tripathi, MD focuses on Cancer and Bladder Cancer. In particular, much of their work with Cancer has involved Stage IV patients, or patients who are Stage III.
Is Abhishek Tripathi, MD currently recruiting for clinical trials?
Yes, Abhishek Tripathi, MD is currently recruiting for 11 clinical trials in Oklahoma City Oklahoma. If you're interested in participating, you should apply.
Are there any treatments that Abhishek Tripathi, MD has studied deeply?
Yes, Abhishek Tripathi, MD has studied treatments such as Pembrolizumab, Gemcitabine Hydrochloride, Nivolumab.
What is the best way to schedule an appointment with Abhishek Tripathi, MD?
Apply for one of the trials that Abhishek Tripathi, MD is conducting.
What is the office address of Abhishek Tripathi, MD?
The office of Abhishek Tripathi, MD is located at: University of Oklahoma Health Sciences Center, Oklahoma City, Oklahoma 73104 United States. This is the address for their practice at the University of Oklahoma Health Sciences Center.
Is there any support for travel costs?
The coverage of travel expenses can vary greatly between different clinical trials. Please see more financial detail in the trials you’re interested to apply.